GlobalData: Eli Lilly cutting insulin price by 70% in US to help it remain dominant player in insulin market; market's future likely to see increased competition driven by federal price-capping, global biosimilars rollout, once-weekly basal insulin launch

Sample article from our Health Care Sector

March 13, 2023 (press release) –

Eli Lilly recently announced that it will reduce the price of its insulin Humalog by 70% in the US and cap the out-of-pocket cost for those on commercial insurance at $35 per month. This is the second time Lilly has significantly reduced the cost of its insulin after lowering the list price of Humalog by 50% in 2019. As a result of these pricing measures, it is likely that Lilly will remain a leading manufacturer in the insulin market and is in a strong position to compete on lower insulin prices, says GlobalData, a leading data and analytics company.

Lilly’s move follows on from recent US federal action, the Inflation Reduction Act, that legislated reducing the Medicare beneficiary insulin out-of-pocket costs at $35 per month.

Akash Patel, Pharma Analyst at GlobalData, comments: “The future of the insulin market is likely to feature increased competition driven by federally mediated price-capping, the rollout of biosimilars across the global market, and the launch of once-weekly basal insulins from Novo Nordisk and Eli Lilly.”

Lilly will likely maintain or increase its market share in the basal insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap. However, there is steadily increasing pressure to its market share in China, with several companies developing insulin lispro biosimilars, and alternative lower-priced insulins such as Viatris’s Semglee (insulin glargine).

Patel concludes: “The increasing wave of patient advocacy for equity of access to insulin will continue to drive down insulin prices and likely lead to competition between Lilly, Sanofi, and Novo Nordisk for the pricing and sales of their major branded insulins. In the face of continued competition, Lilly has developed a recently authorized biosimilar, Rezvoglar, to Sanofi’s leading branded insulin glargine (Lantus).”

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.